Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease.

Permutation testing of model predictivity yielded a significant result for the comparison of groups A-C1 (p∼0.027), and approached significance for A-C2 (p∼0.053).

also in 8,237 other papers

The predictivity of the model was highly significant (p∼0.004) and the analysis of the weights indicated that the main blood serum metabolic differences between patients at diagnosis and in post treatment remission are higher levels of glucose, creatinine and 2-hydroxybutyrate in patients at diagnosis (group A) and elevated concentrations of succinate, 2-hydroxyisobutyrate, 3-hydroxybutyrate, alanine and choline in patients that are in remission (group B) after receiving treatment.

also in 132,142 other papers